Structural elucidation of the neuraminidase inhibitor zanamivir (relenza): Creeping and diffusion for polymorph separation

Naba K. Nath, Nobuhiro Yasuda, Wael Rabeh, Subash Chandra Sahoo, Pance Naumov

Research output: Contribution to journalArticle

Abstract

Zanamivir, the active ingredient of the antiviral drug Relenza, is the most potent of the four currently approved neuraminidase inhibitors for treatment of pandemic strains of influenza. A combination of solution creeping and vapor diffusion of antisolvent was successfully applied to obtain two crystalline polymorphic dihydrates and to accomplish the first structure determination of zanamivir with X-ray diffraction.

Original languageEnglish (US)
Pages (from-to)770-774
Number of pages5
JournalCrystal Growth and Design
Volume14
Issue number2
DOIs
StatePublished - Feb 5 2014

Fingerprint

Zanamivir
influenza
Neuraminidase
Polymorphism
ingredients
inhibitors
drugs
Vapors
vapors
Crystalline materials
X ray diffraction
diffraction
x rays
Antiviral Agents

ASJC Scopus subject areas

  • Chemistry(all)
  • Materials Science(all)
  • Condensed Matter Physics

Cite this

Structural elucidation of the neuraminidase inhibitor zanamivir (relenza) : Creeping and diffusion for polymorph separation. / Nath, Naba K.; Yasuda, Nobuhiro; Rabeh, Wael; Sahoo, Subash Chandra; Naumov, Pance.

In: Crystal Growth and Design, Vol. 14, No. 2, 05.02.2014, p. 770-774.

Research output: Contribution to journalArticle

@article{22a2300b26724411aa3a7c505a38390f,
title = "Structural elucidation of the neuraminidase inhibitor zanamivir (relenza): Creeping and diffusion for polymorph separation",
abstract = "Zanamivir, the active ingredient of the antiviral drug Relenza, is the most potent of the four currently approved neuraminidase inhibitors for treatment of pandemic strains of influenza. A combination of solution creeping and vapor diffusion of antisolvent was successfully applied to obtain two crystalline polymorphic dihydrates and to accomplish the first structure determination of zanamivir with X-ray diffraction.",
author = "Nath, {Naba K.} and Nobuhiro Yasuda and Wael Rabeh and Sahoo, {Subash Chandra} and Pance Naumov",
year = "2014",
month = "2",
day = "5",
doi = "10.1021/cg4016383",
language = "English (US)",
volume = "14",
pages = "770--774",
journal = "Crystal Growth and Design",
issn = "1528-7483",
publisher = "American Chemical Society",
number = "2",

}

TY - JOUR

T1 - Structural elucidation of the neuraminidase inhibitor zanamivir (relenza)

T2 - Creeping and diffusion for polymorph separation

AU - Nath, Naba K.

AU - Yasuda, Nobuhiro

AU - Rabeh, Wael

AU - Sahoo, Subash Chandra

AU - Naumov, Pance

PY - 2014/2/5

Y1 - 2014/2/5

N2 - Zanamivir, the active ingredient of the antiviral drug Relenza, is the most potent of the four currently approved neuraminidase inhibitors for treatment of pandemic strains of influenza. A combination of solution creeping and vapor diffusion of antisolvent was successfully applied to obtain two crystalline polymorphic dihydrates and to accomplish the first structure determination of zanamivir with X-ray diffraction.

AB - Zanamivir, the active ingredient of the antiviral drug Relenza, is the most potent of the four currently approved neuraminidase inhibitors for treatment of pandemic strains of influenza. A combination of solution creeping and vapor diffusion of antisolvent was successfully applied to obtain two crystalline polymorphic dihydrates and to accomplish the first structure determination of zanamivir with X-ray diffraction.

UR - http://www.scopus.com/inward/record.url?scp=84893691512&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893691512&partnerID=8YFLogxK

U2 - 10.1021/cg4016383

DO - 10.1021/cg4016383

M3 - Article

AN - SCOPUS:84893691512

VL - 14

SP - 770

EP - 774

JO - Crystal Growth and Design

JF - Crystal Growth and Design

SN - 1528-7483

IS - 2

ER -